Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
This IMWG consensus provides recommendations on the use of 18fluorodeoxyglucose (18F-FDG) PET/CT in multiple myeloma patients and other plasma cell disorders, including smoldering multiple myeloma and solitary plasmacytoma.
(18F-FDG) PET/CT assesses bone damage with relatively high sensitivity and specificity, and detects extramedullary sites of proliferating clonal plasma cells while providing important prognostic information. If a whole-body MRI is not able to be performed, then 18F-FDG PET/CT is required to confirm a diagnosis of solitary plasmacytoma. Also, 18F-FDG PET/CT should be performed to determine if the myeloma is smoldering or active, especially if whole-body X-ray is negative and a whole-body MRI is not available.
18F-FDG PET/CT is the preferred technique used to distinguish between metabolically active and inactive disease; it is the choice for functional imaging modality to evaluate and to monitor the effect of therapy on myeloma-cell metabolism.
Learn more about the role of role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders.
Prof Michele Cavo, MD, Prof Evangelos Terpos, MD, Cristina Nanni, MD, Prof Philippe Moreau, MD, Suzanne Lentzsch, MD, Prof Sonja Zweegman, MD, Prof Jens Hillengass, MD, Prof Monika Engelhardt, MD, Prof Saad Z Usmani, MD, Prof David H Vesole, MD, Prof Jesus San-Miguel, MD, Prof Shaji K Kumar, MD, Prof Paul G Richardson, MD, Joseph R Mikhael, MD, Fernando Leal da Costa, MD, Prof Meletios-Athanassios Dimopoulos, MD, Chiara Zingaretti, PhD, Prof Niels Abildgaard, MD, Prof Hartmut Goldschmidt, MD, Prof Robert Z Orlowski, MD, Prof Wee Joo Chng, MD, Prof Hermann Einsele, MD, Prof Sagar Lonial, MD, Prof Bart Barlogie, MD, Prof Kenneth C Anderson, MD, Prof S Vincent Rajkumar, MD, Brian G M Durie, MD, Elena Zamagni, MD
Learn more at